Fluorogenic ATP Analog Detection for Kinase Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing protein kinases in vivo are limited by the inability to distinguish between homologous kinases, monitor kinase activity independently of phosphatase activity, and identify new substrates, leading to insufficient in vivo analysis capabilities.
Innovation Solution
Development of fluorogenic ATP or ADP analogs, such as TNP-N6-Benzyl-ATP and MANT-N6-Benzyl-ATP, which become fluorescent upon binding to protein kinases with enlarged ATP binding pockets, enabling live cell protein kinase analysis and differentiation between homologous kinases, and detection of kinase activity without requiring well-defined substrates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If fusion protein methods with sensing domains and reporter domains are used to monitor kinase activity in vivo, then kinase activity can be monitored, but the methods cannot differentiate between homologous kinases that share the same substrates
Solution Approach 1:
The patent applies local quality by creating localized structural modifications in the ATP binding pocket through site-directed mutagenesis. Specific amino acid substitutions (e.g., M227G in Akt1, M196G in Akt2) enlarge the binding pocket to accommodate bulky ATP analogs, providing a unique local structural feature that enables kinase differentiation while maintaining catalytic function.
Solution Approach 2:
The patent changes physical and chemical parameters by introducing bulky N6-substituted ATP analogs (with groups like trinitrophenyl, N-methylanthraniloyl, or 2,4,6-triiodophenyl) that differ in size, shape, and fluorescent properties. These parameter changes allow the modified kinases to selectively bind and process these analogs, enabling differentiation between homologous kinases through detection of the incorporated analogs.
2Measurement precision
If conventional ATP analogs are used for kinase detection, then kinase activity can be detected, but the analogs cannot penetrate cell membranes to enable in vivo analysis
Solution Approach 1:
The patent uses cell-penetrating peptides (CPPs) such as TAT, penetratin, or R9 as intermediaries to facilitate the entry of bulky ATP analogs into living cells. These peptides act as carriers that temporarily complex with the ATP analogs, enable their transport across the cell membrane, and then release them inside the cell where they can be processed by the modified kinases.
3Measurement precision
If fusion protein strategies are used for kinase analysis, then some kinase activity can be monitored, but the methods monitor equilibrium of opposite effects of kinase and phosphatase activities instead of solely kinase activity
Solution Approach 1:
The patent applies preliminary action by pre-modifying the kinase's ATP binding pocket through site-directed mutagenesis before introducing the ATP analogs. This structural modification creates a selective environment that favors binding of the modified ATP analogs, allowing the kinase's intrinsic catalytic activity to be measured directly without being confounded by phosphatase activity or equilibrium effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate, high-throughput screening for protein kinase modulators and regulation studies in live cells, distinguishing between homologous kinases and identifying new substrates, thereby improving the analysis of protein kinase activity in vivo.
Implementation Method 1
the ATP or ADP analogs become fluorescent upon specific binding to a protein kinase with an enlarged ATP binding pocket
Data Source
AI summary
Provided herein is a method and system for detecting kinase activity, comprising: providing one or more mutated kinases, wherein the one or more mutated kinases comprise a mutation that enlarges an ATP binding pocket of the kinase; contacting the one or more mutated kinases with an ATP or ADP analog-nanoparticle conjugate capable of intracellular delivery of the ATP orADP analog-nanoparticle conjugate, wherein the ATP or ADP analog comprises a detectable label; assaying the one or more mutated kinases under conditions in which the ATP or ADP analog-nanoparticle conjugate contacts the one or more mutated kinases, wherein the one or more kinases react to transfer the detectable label to the substrate, wherein the ATP analog only fluoresces upon contact with the ATP binding pocket of the kinase.